Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Sep 30, 2026, 3:45 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 72 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Asthma Placebo Effects Clear all
Completed Phase 3 Interventional Results available

A Study to Evaluate the Onset of Effect and Time Course of Change in Lung Function With Benralizumab in Severe, Uncontrolled Asthma Patients With Eosinophilic Inflammation

NCT02869438
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
16
States / cities
Scottsboro, Alabama • Gilbert, Arizona • Denver, Colorado + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Potential Effect of Benralizumab on the Humoral Immune Response to the Seasonal Influenza Vaccination in Adolescent and Young Adult Patients With Severe Asthma

NCT02814643
View directory record Official record
Conditions
Asthma
Interventions
Benralizumab, Benralizumab Placebo, Seasonal influenza virus vaccine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 21 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
24
States / cities
Birmingham, Alabama • Mesa, Arizona • Huntington Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2018 · Synced Sep 30, 2026, 3:45 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation

NCT02937168
View directory record Official record
Conditions
Asthma
Interventions
Reslizumab, Fludeoxyglucose F 18 (FDG), Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 9, 2021 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 4 Interventional Results available

The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma

NCT04400318
View directory record Official record
Conditions
Asthma
Interventions
Dupilumab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 70 Years
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
10
States / cities
Westminster, California • Kansas City, Kansas • Ann Arbor, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Effect of Tezepelumab on the Immune Response to Influenza Vaccination in Participants With Asthma

NCT05062759
View directory record Official record
Conditions
Moderate to Severe Asthma
Interventions
Tezepelumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 21 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
15
States / cities
Bakersfield, California • Huntington Beach, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Sep 30, 2026, 3:45 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528

NCT00483041
View directory record Official record
Conditions
Asthma
Interventions
PLACEBO, MEDI528 9 mg/kg
Other · Biological
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
4
States / cities
Boston, Massachusetts • St Louis, Missouri • Winston-Salem, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2014 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

NCT01316315
View directory record Official record
Conditions
Asthma
Interventions
Active, Placebo
Drug
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
2
States / cities
Denver, Colorado • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 5, 2014 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Tezepelumab on Airway Inflammation in Adults With Uncontrolled Asthma (CASCADE)

NCT03688074
View directory record Official record
Conditions
Asthma, Bronchial Diseases, Respiratory Tract Diseases, Lung Diseases, Obstructive, Lung Diseases, Respiratory Hypersensitivity, Hypersensitivity, Immediate, Hypersensitivity, Immune System Diseases
Interventions
Tezepelumab, Placebo
Biological · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Denver, Colorado • New Haven, Connecticut • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 1 Interventional

A Study To Determine The Effect Of SB-480848 On Asthma

NCT00368576
View directory record Official record
Conditions
Atherosclerosis
Interventions
SB 480848, tablets
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
4
States / cities
Cypress, California • Normal, Illinois • North Dartmouth, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 3 Interventional

A Study to Investigate the Effect on Lung Function of BDA Formulated With a Next Generation Propellant Compared With an Approved Asthma Treatment (BDA With HFA Propellant) in Participants With Asthma

NCT06502366
View directory record Official record
Conditions
Asthma
Interventions
BDA MDI HFO 160/180 μg, BDA MDI HFA 160/180 μg, Placebo MDI HFA
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
70
States / cities
Mobile, Alabama • Sheffield, Alabama • Phoenix, Arizona + 66 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 2 Interventional Results available

A Study Evaluating the Effect of Inhaled PT007(AS MDI) Versus Placebo MDI and Ventolin Evohaler on Lung Function in Adult Participants With Asthma

NCT06644924
View directory record Official record
Conditions
Asthma
Interventions
Intervention: AS MDI, Intervention: Ventolin Evohaler, Intervention: Placebo matching AS MDI
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
22
States / cities
Encinitas, California • Lancaster, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of 20,000 EU of Clinical Center Reference Endotoxin (CCRE) Versus Placebo(ENDOHEART)

NCT03623022
View directory record Official record
Conditions
Healthy
Interventions
Clinical Center Reference Endotoxin (CCRE), Normal saline
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 50 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 20, 2019 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety, Tolerability and Effects of AZD8630 in Healthy Subjects and Subjects With Asthma on Inhaled Corticosteroids and Long-acting Beta-agonists

NCT05110976
View directory record Official record
Conditions
Asthma
Interventions
AZD8630, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
18
States / cities
Tempe, Arizona • Bakersfield, California • Glendale, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2023 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 1 Interventional

A Phase I Study in Asthma Patients Evaluating the Effect of Doses of FlutiForm™ on the Amount, if Any, of Cortisol Produced by the Adrenal Glands

NCT00657774
View directory record Official record
Conditions
Asthma
Interventions
FlutiForm 250/10 ug, FlutiForm 100/10 ug, Oral Prednisone 10mg, Placebo
Drug
Lead sponsor
SkyePharma AG
Industry
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
19
States / cities
Phoenix, Arizona • Anaheim, California • Long Beach, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2008 · Synced Sep 30, 2026, 3:45 PM EDT
Terminated Phase 3 Interventional

A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.

NCT05763121
View directory record Official record
Conditions
Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Interventions
Dexpramipexole Dihydrochloride, Placebo
Drug
Lead sponsor
Areteia Therapeutics
Industry
Eligibility
12 Years to 99 Years
Enrollment
1,061 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
89
States / cities
Bakersfield, California • La Palma, California • Newport Beach, California + 73 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Safety and Effects of MN-221 in Subjects With Moderate to Severe Asthma

NCT00679263
View directory record Official record
Conditions
Asthma
Interventions
MN-221, Placebo
Drug
Lead sponsor
MediciNova
Industry
Eligibility
18 Years to 50 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
4
States / cities
Lenexa, Kansas • North Dartmouth, Massachusetts • Rolla, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 19, 2011 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 4 Interventional

Asthma in the Elderly: The Effect of Montelukast

NCT02635334
View directory record Official record
Conditions
Asthma
Interventions
Montelukast 10 mg orally, Placebo
Drug · Other
Lead sponsor
Rohr and Columbo Asthma, Allergy and Immunology Specialists, P.C.
Other
Eligibility
65 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Bryn Mawr, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 5, 2016 · Synced Sep 30, 2026, 3:45 PM EDT
Terminated Phase 2 Interventional Results available

Bosentan for Poorly Controlled Asthma

NCT00815347
View directory record Official record
Conditions
Asthma
Interventions
bosentan, placebo
Drug
Lead sponsor
UConn Health
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Farmington, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study to Compare Formoterol Fumerate in the Pressair DPI to the Foradil Aerolizer in Patient With Mild to Moderate Asthma

NCT01641081
View directory record Official record
Conditions
Asthma
Interventions
Formoterol Fumarate in the Pressair DPI, Low Dose, Formoterol Fumarate in the Pressair DPI, High Dose, Foradil Aerolizer, Low Dose, Foradil Aerolizer, High Dose, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
174 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
29
States / cities
Phoenix, Arizona • Encinitas, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 4 Interventional Results available

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

NCT00267202
View directory record Official record
Conditions
Allergic Asthma
Interventions
Placebo, Omalizumab, Immunotherapy
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 55 Years
Enrollment
275 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 14, 2016 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 2 Interventional Results available

Single Dose Study of the Effect of Formoterol Fumarate in Combination With Mometasone Furoate Inhaled Via a Pressurized Metered Dose Inhaler (pMDI) in Children Aged 5-11 Years Old With Persistent Asthma

NCT00746330
View directory record Official record
Conditions
Asthma
Interventions
Mometasone furoate/formoterol fumarate (MFF), Formoterol fumarate 12 μg pMDI (F12M), Formoterol fumarate 12 μg DPI (F12D), Placebo to F12D, Placebo to F12M/MFF
Drug
Lead sponsor
Novartis
Industry
Eligibility
5 Years to 11 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
6
States / cities
Mobile, Alabama • Huntington Beach, California • Orange, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating the Effect of IMA-638 in Subjects With Persistent Asthma

NCT00425061
View directory record Official record
Conditions
Asthma
Interventions
IMA-638, placebo
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 80 Years
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
76
States / cities
Birmingham, Alabama • Montgomery, Alabama • Little Rock, Arkansas + 66 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2015 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Effect of Dupilumab on Exercise Capacity in Adult Patients With Asthma

NCT04203797
View directory record Official record
Conditions
Asthma
Interventions
dupilumab, Matching placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Rolling Hills Estates, California • Torrance, California • Westminster, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2024 · Synced Sep 30, 2026, 3:45 PM EDT
Completed Phase 2 Interventional Results available

Dose Ranging Efficacy And Safety With Mepolizumab in Severe Asthma

NCT01000506
View directory record Official record
Conditions
Asthma
Interventions
Mepolizumab 750, Mepolizumab 250, Mepolizumab 75, Placebo saline
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years to 65 Years
Enrollment
621 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
21
States / cities
Long Beach, California • Los Angeles, California • Riverside, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 24, 2018 · Synced Sep 30, 2026, 3:45 PM EDT